BioCentury
ARTICLE | Clinical News

Amarillo misses Phase III Sjogren's end point

January 5, 2001 8:00 AM UTC

AMAR said that its second U.S. Phase III trial of oral interferon alpha did not meet its primary end point of increasing Stimulated whole saliva (SWS) and reducing subjective measures of dry mouth. Ho...